Granisetron - Isotope Labelled Standards
References
FAQ's
References
- Bermudez, Jose; Fake, Charles S.; Joiner, Graham F.; Joiner, Karen A.; King, Frank D.; Miner, Wesley D.; Sanger, Gareth J., 5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives, Journal of Medicinal Chemistry, Volume: 33, Issue: 7, Pages: 1924-9, 1990
- Kudoh, Shinobu; Sato, Tomoyuki; Okada, Hideki; Kumakura, Hiroyuki; Nakamura, Hiroshi, Simultaneous determination of granisetron and 7-hydroxygranisetron in human plasma by high-performance liquid chromatography with fluorescence detection, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 660, Issue: 1, Pages: 205-10, 1994
Frequently Asked Questions
Are Granisetron impurities regulated differently in different countries?
While there may be variations in impurity regulations between countries, the fundamental objective remains the same: to ensure the safety and quality of Granisetron.
How are Granisetron impurities classified?
Impurities in Granisetron are classified as organic or inorganic impurities, related substances, or degradation products based on their origin and chemical nature.
Can Granisetron impurities interact with other medications?
Some impurities in Granisetron may have the potential to interact with other medications, which highlights the importance of considering potential drug interactions during treatment.
How should Granisetron impurities be stored in terms of temperature?
The recommendation is to store Granisetron impurities at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.